Clinical trial
The Efficacy and Safety of Colchicine in Pulmonary Artery Hypertension Patients
NCT07907757 is registered in ClinicalTrials.gov with Ain Shams University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Efficacy and Safety of Colchicine in Pulmonary Artery Hypertension Patients
- Lead sponsor
- Ain Shams University
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- October 31, 2027
- Enrollment
- 60 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
pulmonary hypertension
Arms
As registered; 2 arms.
-
No intervention: Control group
No intervention: Control group: Thirty patients shall receive standard of care treatment for 12 weeks.
Standard of care treatment received by both groups would include pulmonary vasodilator therapy with Phosphodiesterase 5 inhibitors (PDE5), Endothelin receptor antagonists (ERA), and Prostacyclin analogues (PA), either alone or in combination, without any consideration by the treating medical team for escalation of treatment.
-
Experimental: Colchicine
Experimental: Colchicine group: Thirty patients shall receive standard of care treatment in addition to 0.5 mg colchicine tablets per oral once daily for 12 weeks (Colchicine®, Tablets with a concentration of 500 micrograms, manufactured by Adwick-Al Nasr Pharmaceutical Chemicals Company, Abu Zaabal, Egypt).
Primary endpoints
Registered primary outcome measures; 1 primary.
-
WHO-FC
One of the strongest predictors of survival at diagnosis and follow-up and worsening WHO-FC is one of the most alarming indicators of disease progression, which should trigger further investigation to identify the cause(s) of clinical deterioration
Lead sponsor's other trials
Ain Shams University, most recent start first.
+1,948 more trials See the organization page
Similar trials
Same condition (Hypertension, Pulmonary) and phase, most recent start first.
+129 more trials See the condition page